BioCorRx Inc. (BICX)
OTCMKTS: BICX · Delayed Price · USD
0.750
0.00 (0.00%)
Apr 26, 2024, 11:36 AM EDT - Market closed
BioCorRx Revenue
In the year 2023, BioCorRx had annual revenue of $89.16K, a decrease of -58.31%. Revenue in the quarter ending December 31, 2023 was $18.94K, a -77.15% decrease year-over-year.
Revenue (ttm)
$89.16K
Revenue Growth
-58.31%
P/S Ratio
93.22
Revenue / Employee
$29,720
Employees
3
Market Cap
8.31M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
Dec 31, 2020 | 122.62K | -117.64K | -48.96% |
Dec 31, 2019 | 240.26K | -136.40K | -36.21% |
Dec 31, 2018 | 376.66K | -280.62K | -42.69% |
Dec 31, 2017 | 657.27K | -44.50K | -6.34% |
Dec 31, 2016 | 701.77K | -222.96K | -24.11% |
Dec 31, 2015 | 924.73K | -246.19K | -21.03% |
Dec 31, 2014 | 1.17M | 455.96K | 63.77% |
Dec 31, 2013 | 714.96K | -153.20K | -17.65% |
Dec 31, 2012 | 868.16K | 96.40K | 12.49% |
Dec 31, 2011 | 771.76K | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
BICX News
- 4 weeks ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 4 weeks ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 2 months ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire
- 3 months ago - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - GlobeNewsWire
- 4 months ago - BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President - GlobeNewsWire
- 6 months ago - BioCorRx Reports Business Update for the Third Quarter of 2023 - GlobeNewsWire
- 9 months ago - BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder - GlobeNewsWire
- 9 months ago - BioCorRx Reports Business Update for the Second Quarter of 2023 - GlobeNewsWire